Cargando…
Pharmaceutical marketing: the example of drug samples
Branded drug samples are one of the most important promotional tools that pharmaceutical manufactures employ. Pharmaceutical sales representatives (“drug reps”) use samples to gain access to physicians and other prescribers. Sample provision is closely intertwined with visits by drug reps; detailing...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640882/ https://www.ncbi.nlm.nih.gov/pubmed/36345038 http://dx.doi.org/10.1186/s40545-022-00479-z |
_version_ | 1784825962105405440 |
---|---|
author | Alagha, Emily Couvillon Fugh-Berman, Adriane |
author_facet | Alagha, Emily Couvillon Fugh-Berman, Adriane |
author_sort | Alagha, Emily Couvillon |
collection | PubMed |
description | Branded drug samples are one of the most important promotional tools that pharmaceutical manufactures employ. Pharmaceutical sales representatives (“drug reps”) use samples to gain access to physicians and other prescribers. Sample provision is closely intertwined with visits by drug reps; detailing visits convince physicians to try new products, while sampling maintains the flow of prescriptions. Only drugs with the highest profit margins are sampled. Although physicians believe that samples save patients money, patients who receive samples have higher overall out-of-pocket costs. Most studies have found that patients in financial need are least likely to receive samples. Pharmaceutical marketers pitch samples as a low-risk way to deal with diagnostic uncertainty. In fact, there is no evidence that samples aid diagnosis. Sample availability may compromise patient safety by reducing compliance with guidelines and steering patients towards newer drugs, for which adverse effects have not been well-delineated. Although physicians believe that samples improve adherence for low-income patients, branded samples do not improve access or adherence Samples are not a charitable activity, but are instead a highly effective form of drug marketing. Sampling of branded drugs increase drug costs for everyone. Only a cohesive effort by clinicians, legislators and policymakers can end this practice. Evidence supports a ban on sample distribution of branded products. |
format | Online Article Text |
id | pubmed-9640882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96408822022-11-14 Pharmaceutical marketing: the example of drug samples Alagha, Emily Couvillon Fugh-Berman, Adriane J Pharm Policy Pract Commentary Branded drug samples are one of the most important promotional tools that pharmaceutical manufactures employ. Pharmaceutical sales representatives (“drug reps”) use samples to gain access to physicians and other prescribers. Sample provision is closely intertwined with visits by drug reps; detailing visits convince physicians to try new products, while sampling maintains the flow of prescriptions. Only drugs with the highest profit margins are sampled. Although physicians believe that samples save patients money, patients who receive samples have higher overall out-of-pocket costs. Most studies have found that patients in financial need are least likely to receive samples. Pharmaceutical marketers pitch samples as a low-risk way to deal with diagnostic uncertainty. In fact, there is no evidence that samples aid diagnosis. Sample availability may compromise patient safety by reducing compliance with guidelines and steering patients towards newer drugs, for which adverse effects have not been well-delineated. Although physicians believe that samples improve adherence for low-income patients, branded samples do not improve access or adherence Samples are not a charitable activity, but are instead a highly effective form of drug marketing. Sampling of branded drugs increase drug costs for everyone. Only a cohesive effort by clinicians, legislators and policymakers can end this practice. Evidence supports a ban on sample distribution of branded products. BioMed Central 2022-11-07 /pmc/articles/PMC9640882/ /pubmed/36345038 http://dx.doi.org/10.1186/s40545-022-00479-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Alagha, Emily Couvillon Fugh-Berman, Adriane Pharmaceutical marketing: the example of drug samples |
title | Pharmaceutical marketing: the example of drug samples |
title_full | Pharmaceutical marketing: the example of drug samples |
title_fullStr | Pharmaceutical marketing: the example of drug samples |
title_full_unstemmed | Pharmaceutical marketing: the example of drug samples |
title_short | Pharmaceutical marketing: the example of drug samples |
title_sort | pharmaceutical marketing: the example of drug samples |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640882/ https://www.ncbi.nlm.nih.gov/pubmed/36345038 http://dx.doi.org/10.1186/s40545-022-00479-z |
work_keys_str_mv | AT alaghaemilycouvillon pharmaceuticalmarketingtheexampleofdrugsamples AT fughbermanadriane pharmaceuticalmarketingtheexampleofdrugsamples |